Biotech firm ValiRx has appointed a Chief Operating Officer to assist in building and adding value to its portfolio of technologies and to coordinate ValiRx's commercial strategy.
Samual Ogunsalu has a background in Microbiology and Biochemical engineering and has 15 years' experience in the identification and commercialisation of early and mid-stage life-science opportunities and in the out-licensing of portfolio technologies.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dr Satu Vainikka, the group's Chief Executive Officer, said: "I am delighted to be working with Sam again, this time under the ValiRx umbrella and I look forward to benefitting from his past experience, contacts and intimate understanding of the challenges associated with the commercialisation and further development of companies and technologies in our space.
"ValiRx is now ready to change gear and Sam will help us to exploit value in our IP portfolio and prepare the group for out-licensing partnerships and taking ValiRx to the next stage."
The share price rose 1.77% to 0.57p by 13:25.
NR
-
Could your family be at risk of an unexpected tax bill? How to keep your loved ones in the loopMany families are out of the loop when it comes to planning the financial aspects of both retirement and inheritance
-
Rightmove: Glut of homes for sale in southern England drives asking price dropAsking prices are 0.1% lower than a year ago, according to the property website, driven by challenges in affordability-stretched London and the south
